Effect of ziprasidone dose on rates of medication discontinuation in acute schizophrenia or schizoaffective disorder

被引：0
|
作者：
Karayal, O.
Citrome, L. [2 ]
Yang, R. [1 ]
Harnett, J. [3 ]
Glue, P. [4 ]
机构：
[1] Pfizer Inc, Statistics, New York, NY USA
[2] Nathan S Kline Inst Psychiat Res, New York, NY USA
[3] Pfizer Inc, Global Outcomes, New York, NY USA
[4] Pfizer Inc, Clin Sci Grp, New York, NY USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2008年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：160 / 160
页数：1
相关论文
共 50 条
  • [31] The efficacy and safety of ziprasidone 80 mg/day and 160 mg/day in schizophrenia and schizoaffective disorder
    Daniel, D
    Reeves, K
    Harrigan, EP
    SCHIZOPHRENIA RESEARCH, 1997, 24 (1-2) : 204 - 204
  • [32] Aripiprazole Dose-Response Relationship in Schizophrenia and Schizoaffective Disorder
    Mace, Shubhra
    Taylor, David
    CNS DRUGS, 2009, 23 (09) : 773 - 780
  • [33] Effects of oral ziprasidone and risperidone on cognitive functioning in patients with schizophrenia or schizoaffective disorder: Preliminary data
    Mitchell, D
    Hagger, C
    Wise, AL
    Schulz, SC
    SCHIZOPHRENIA RESEARCH, 1997, 24 (1-2) : 116 - 116
  • [34] Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: A randomized, double-blind, flexible-dose, multicenter study
    Perkins, Diana O.
    Gu, Hongbin
    Weiden, Peter J.
    McEvoy, Joseph P.
    Hamer, Robert M.
    Lieberman, Jeffrey A.
    JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (01) : 106 - 113
  • [35] Effect of initial ziprasidone dose on treatment persistence in schizophrenia
    Mullins, CD
    Shaya, FT
    Zito, JM
    Obeidat, N
    Naradzay, J
    Harrison, DJ
    SCHIZOPHRENIA RESEARCH, 2006, 83 (2-3) : 277 - 284
  • [36] Effect of initial ziprasidone dose on length of therapy in schizophrenia
    Joyce, AT
    Harrison, DJ
    Loebel, AD
    Carter, CT
    Ollendorf, DA
    SCHIZOPHRENIA RESEARCH, 2006, 83 (2-3) : 285 - 292
  • [37] Clinical and Pharmacokinetic Characteristics of Ziprasidone Single Versus Divided Dose Administration in Schizoaffective Disorder: A Casuistics
    Regenthal, Ralf
    Kuenstler, Ulf
    Fried, Franziska
    Teichert, Jens
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 104 (06) : 512 - 512
  • [38] Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial
    P. Keck Jr
    Alan Buffenstein
    James Ferguson
    John Feighner
    William Jaffe
    Edmund P. Harrigan
    Marilyn R. Morrissey
    Psychopharmacology, 1998, 140 : 173 - 184
  • [39] Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder
    Canuso, CM
    Goldstein, JM
    Wojcik, J
    Dawson, R
    Brandman, D
    Klibanski, A
    Schildkraut, JJ
    Green, AI
    PSYCHIATRY RESEARCH, 2002, 111 (01) : 11 - 20
  • [40] Psychotropic Medication Use Among Adults With Schizophrenia and Schizoaffective Disorder in the United States
    Stroup, T. Scott
    Gerhard, Tobias
    Crystal, Stephen
    Huang, Cecilia
    Tan, Zhiqiang
    Wall, Melanie M.
    Mathai, Chacku M.
    Olfson, Mark
    PSYCHIATRIC SERVICES, 2018, 69 (05) : 605 - 608
12345